{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:20:56Z","timestamp":1791411656642,"version":"4.3.3"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":187,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1177\/0091270011417717","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T10:22:50Z","timestamp":1317378170000},"page":"1430-1435","source":"Crossref","is-referenced-by-count":18,"title":["Linezolid Pharmacokinetics in Patients With Acute Renal Failure Undergoing Continuous Venovenous Hemodiafiltration"],"prefix":"10.1002","volume":"52","author":[{"given":"Esther","family":"Carcelero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Soy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Poch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2002.00509.x"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.7.813"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0B013E3181611F552"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.17105"},{"issue":"17","key":"e_1_2_7_6_2","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1681\/ASN.V12suppl_1s40","article-title":"What is the renal replacement method of first choice for intensive care patients?","volume":"12","author":"Vanholder R","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746120-00003"},{"issue":"2","key":"e_1_2_7_8_2","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram\u2010positive infections","volume":"51","author":"MacGowan AP","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.5.1345-1351.2002"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342150-00007"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342130-00004"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.03.037"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.8.1071.32874"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.farma.2009.07.001"},{"key":"e_1_2_7_15_2","unstructured":"Department of Health and Human Services US Food and Drug Administrationhttp:www.fda.govcderguidance4252fnl.pdf. Accessed September 1 2010.http:www.fda.govcderguidancecmc3.pdf. Accessed September 1 2010.http:www.fda.govcbergdlnsmethval.pdf. Accessed September 1 2010."},{"key":"e_1_2_7_16_2","unstructured":"The European Agency for the Evaluation of Medicinal Products (Europe).http:www.emea.europa.euhtmsvetvetguidelinesquality.htm. Accessed September 1 2010.http:www.emea.europa.eupdfshumanich038195en.pdf. Accessed September 1 2010."},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600720843"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.05.004"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1128\/AAC.41.12.2640","article-title":"Pharmacokinetics of imipenem\u2010cilastatin in critically ill patients undergoing continuous venovenous hemofiltration","volume":"41","author":"Tegeder I","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.152"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270011417717","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270011417717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T06:19:30Z","timestamp":1698646770000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270011417717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1177\/0091270011417717"],"URL":"https:\/\/doi.org\/10.1177\/0091270011417717","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}